Press Releases

April 16th, 2024

SGO/GOG-F Launch BRIDGES 2.0 Research Initiative
Read More arrow icon

August 1st, 2023

Thomas J. Herzog, MD takes office as The GOG Foundation, Inc. President
Read More arrow icon

March 27th, 2023

ENGOT-EN6-NSGO/GOG-3031/RUBY Trial Results Press Release
Read More arrow icon

March 25th, 2023

GOG 3026 Press Release
Read More arrow icon

February 3rd, 2023

NRG-GY018 Press Release
Read More arrow icon

March 31st, 2022

GOG 3020 (ATHENA) /ENGOT-ov45 trial (ATHENA-MONO) Press Release
Read More arrow icon

March 15th, 2021

Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival
Read More arrow icon

December 16th, 2020

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study
Read More arrow icon

December 9th, 2020

Verastem Oncology Initiates Phase 2 Registration-Directed Trial (GOG-3052) of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Read More arrow icon

May 3rd, 2020

FDA Approves Niraparib as Maintenance Treatment in Women with Advanced Ovarian, Fallopian and Primary Peritoneal Cancer Regardless of Biomarker Status
Read More arrow icon
Showing posts 1 - 10 of 44.